Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer

Clinical Breast Cancer

Volumn 11, Issue 2, 2011, Pages 129-134

  Petrarca, Cristiane Rios ^a   Brunetto, Andre T ^a   Duval, Vinicius ^a   Brondani, Adriana ^b   Carvalho, Gisele Pereira ^a   Garicochea, Bernardo ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Breast cancer; Complete pathologic response; Neoadjuvant chemotherapy; Predictive biomarker; Survivin

Indexed keywords

CYCLIN D1; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PROTEIN BCL 2; PROTEIN ETS1; PROTEIN PDEF; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; TUMOR BIOPSY;

EID: 80051768869     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.03.002     Document Type: Article

References (35)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85. (Pubitemid 28363030)
2. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-7. (Pubitemid 29517908)
3. Goldhirsch A. Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
4. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100. (Pubitemid 28041584)
5. Smith IE. Neoadjuvant/presurgical treatments. Breast Cancer Res 2008;10(suppl 4):24.
6. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
7. Blanc-Brude OP, Mesri M, Wall NR, et al. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003;9:2683-92. (Pubitemid 36842114)
8. Hoffmann AC, Vallbohmer D, Grimminger P, et al. Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 2010;11:341-7.
9. Son BH, Choi JS, Lee JH. Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast. Pathology 2005;37:131-6. (Pubitemid 40593404)
10. Knutsen A, Adell G. Sun XF. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:149-55. (Pubitemid 39165479)
11. Feldman RJ, Sementchenko VI, Gayed M, et al. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003;63:4626-31. (Pubitemid 36951040)
12. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003;303:11-34. (Pubitemid 36151767)
13. Turcotte S, Forget MA, Beauseigle D, et al. Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer. Neoplasia 2007;9:788-96. (Pubitemid 47623418)
14. Katayama S, Nakayama T, Ito M, et al. Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopathol 2005;20:119-26. (Pubitemid 40028990)
15. Rudas M, Lehnert M, Huynh A, et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 2008;14:1767-74. (Pubitemid 351469462)
16. Pusztai L, Krishnamurti S, Perez Cardona J, et al. Expression of bAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 2004;22:248-56. (Pubitemid 38725179)
17. Horii R, Akiyama F, Ito Y, Iwase T. Assessment of hormone receptor status in breast cancer. Pathol Int 2007;57:784-90. (Pubitemid 350060601)
18. Hayward JL, Carbone PP, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-8.
19. Schmidt M, Bachhuber A, Victor A, et al. P53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003;129:295-302. (Pubitemid 36791685)
20. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-6. (Pubitemid 40343130)
21. Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002;9:1334-42. (Pubitemid 36097703)
22. Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006;17:597-604.
23. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007;96:639-45.
24. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009;23:285-91.
25. Span PN, Tjan-Heijnen VC, Manders P, et al. High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 2006;98:223-30. (Pubitemid 44050773)
26. Urruticoechea A, Smith Ie, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
27. Radnade KJ, Nerurkar AV, Phulpagar MD, et al.. Expression of survivin and p53 proteins and their correlation with hormone receptor status in indian breast cancer patients. Indian J Med Sci 2009;63:481-90.
28. Chew JS, Shew JY, Huang CS. Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc 2004;103:925-31.
29. Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004;50:1986-93. (Pubitemid 39425834)
30. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:1821-8.
31. Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on Er/Pr and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
32. Owzar K. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. J Clin Oncol 2008;26:1400-1.
33. Wang S, Huang X. Lee Ck, Liu B: Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of survivin. Oncogene 29:4225-36. Epub 2010 May 24.
34. Zhu H, Zhang G, Wang Y, et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Sci 2010;101:1156-62.
35. Ryan B, O'Donovan N, Browne B, et al. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005;92:120-4. (Pubitemid 40188444)